Alirocumab (anti-PCSK9)
Product Sizes
5 mg
£ POA
HY-P9928A-5MG
2 mg
£ POA
HY-P9928A-2MG
1 mg
£ POA
HY-P9928A-1MG
About this Product
- SKU:
- HY-P9928A
- Additional Names:
- REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
- CAS Number:
- 1245916-14-6
- Extra Details:
- Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome; regulates Nrf2/HO-1; HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation[1][2][3][4][5][6][7][8][9][10][11].
- Molecular Weight:
- (146.24 kDa)
- Purity:
- 98.24
- References:
- [1]Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705.|[2]Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44.|[3]Barale C, et al. PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose. Int J Mol Sci. 2025 Jan 24;26(3):1003.|[4]Villard EF, et al. PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab. JACC Basic Transl Sci. 2016 Oct;1(6):419-427.|[5]Zhang X Y, et al. Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice. Frontiers in Pharmacology, 2025, 16: 1528250.|[6]Kühnast S, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014 Oct;55(10):2103-12.|[7]Hassan NF, et al. Alirocumab boosts antioxidant status and halts inflammation in rat model of sepsis-induced nephrotoxicity via modulation of Nrf2/HO-1, PCSK9/HMGB1/NF-ᴋB/NLRP3 and Fractalkine/CX3CR1 hubs. Biomed Pharmacother. 2024 Aug;177:116929.|[8]Wagner J, et al. PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury. Brain Behav Immun. 2024 Jul;119:494-506.|[9]Zhou E, et al. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Pharmacol Res. 2021 May;167:105524.|[10]Croyal M, et al. PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate. Clin Sci (Lond). 2018 May 31;132(10):1075-1083.|[11]Liang L, et al. Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice. Respir Res. 2024 May 18;25(1):213.
- Research Area:
- Cardiovascular Disease; Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- Store at -80[o]C for 2 years
- Type:
- Antibodies
- Pathway:
- Cell Cycle/DNA Damage;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
